Duality Biotherapeutics Reshapes Board and Finance Leadership to Back R&D Strategy

Duality Biotherapeutics, Inc. ( (HK:9606) ) has shared an announcement.

Duality Biotherapeutics has announced a series of senior management and board changes effective March 23, 2026, including the resignation of executive director Si Wen from the board and the remuneration committee for personal career reasons, while she continues to lead human resources. The company has simultaneously appointed long-time R&D leader Hua Haiqing as an executive director, named Zhang Shaoren as chief financial officer, and added Zhu Zhongyuan to the remuneration committee, signaling a reconfiguration of governance and financial leadership to support its drug development strategy.

Hua, who has nearly 15 years of drug discovery experience at international and Chinese pharmaceutical organizations and has led the group’s pipeline and R&D strategy since 2021, will serve a three-year term as executive director under an appointment letter and receive compensation linked to his broader role in the group. The reshuffle aligns experienced scientific and financial executives more closely with the board and key committees, potentially strengthening oversight of R&D investment, capital allocation and incentive structures as Duality Biotherapeutics advances its pipeline in a competitive biotech landscape.

The most recent analyst rating on (HK:9606) stock is a Buy with a HK$493.00 price target. To see the full list of analyst forecasts on Duality Biotherapeutics, Inc. stock, see the HK:9606 Stock Forecast page.

More about Duality Biotherapeutics, Inc.

Duality Biotherapeutics, Inc. is a biopharmaceutical company focused on drug discovery and development, operating through a group structure with subsidiaries. The company develops new drugs and therapeutic pipelines, targeting innovative R&D-driven growth in the global healthcare and life sciences markets.

Average Trading Volume: 736,438

Technical Sentiment Signal: Strong Sell

Current Market Cap: HK$25.26B

For detailed information about 9606 stock, go to TipRanks’ Stock Analysis page.